

### Curriculum Vitae

\* Within 3 pages

<b>Name in Full</b>	Jeong Il Yu
<b>Country</b>	Korea, Republic of
<b>Affiliation</b>	Assistant Professor Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
<b>Email</b>	ro.yuji651@gmail.com

Educational Background	
1999~2005	MD at CHA University, College of Medicine (former School of Medicine, Pocheon Cha University)
2008~2012	Master's course and a degree The graduate school, Chungbuk National University, Chongju-si, Korea
2012~2017	Ph.D.'s course and a degree The graduate school, Sungkyunkwan University School of Medicine, Seoul, Korea

Professional Career	
2013~2015	Clinical fellow, Department of Radiation Oncology, Samsung Medical Center, Seoul
2015~2016	Instructor, Department of Radiation Oncology, Samsung Medical Center, Seoul
2016~2018	Clinical Assistant Professor, Department of Radiation Oncology, Samsung Medical Center, Seoul
2019~	Assistant Professor, Department of Radiation Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul

Research Field	
Gastro-Intestinal Radiation Oncology	
Radiation Immune-modulation	

## Beyond the COVID-19 Pandemic, Enjoy the Collaboration and Innovation in GI Intervention!

1. Yu JI, Yoo GS, Park HC, et al: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. *Ann Surg Oncol*, 2022
2. Yu JI, Kang W, Yoo GS, et al: Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocellular Carcinoma With Macroscopic Tumor Thrombosis. *Front Oncol* 12:888755, 2022
3. Park JS, Yu JI, Lim DH, et al: Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer. *Biomedicines* 10, 2022
4. Bae BK, Park HC, Yoo GS, et al: The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. *Cancers (Basel)* 14, 2022
5. Yu JI, Park HC, Yoo GS, et al: Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma. *Sci Rep* 11:2614, 2021
6. Kim N, Yu JI, Lim DH, et al: Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. *Front Immunol* 12:701668, 2021
7. Kim K, Yu JI, Jung W, et al: Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). *Eur J Cancer* 157:31-39, 2021
8. Yu JI, Park HC, Yoo GS, et al: Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma. *Cancers (Basel)* 12, 2020
9. Yu JI, Park HC, Lee J, et al: Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. *Cancers (Basel)* 12, 2020
10. Yu JI, Choi C, Lee J, et al: Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. *Radiother Oncol* 152:19-25, 2020
11. Yoo GS, Yu JI, Park HC, et al: Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? *Cancers (Basel)* 12, 2020
12. Yoo GS, Yu JI, Cho S, et al: Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. *Radiother Oncol* 146:187-193, 2020
13. Yoo GS, Park HC, Yu JI, et al: Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. *Cancer Res Treat* 52:446-454, 2020
14. Park SH, Lim DH, Sohn TS, et al: A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. *Ann Oncol*, 2020
15. Park JS, Yu JI, Lim DH, et al: Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. *Cancers (Basel)*

Beyond the COVID-19 Pandemic, Enjoy the Collaboration and Innovation in GI Intervention!  
13, 2020

16. Kim N, Yu JI, Park HC, et al: Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. *Cancer Immunol Immunother*, 2020
17. Cho WK, Yu JI, Park HC, et al: Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. *Tumori*:300891620937795, 2020
18. Baek JY, Yu JI, Park HC, et al: Determining whether postoperative chemoradiotherapy is required in patients with pathologic T3N0 rectal cancer with negative resection margin. *Int J Colorectal Dis* 35:2239-2248, 2020